| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 1997;64:1120-1125
© 1997 The Society of Thoracic Surgeons
Department of Thoracic and Cardiovascular Surgery, The Cleveland Clinic Foundation, Cleveland, Ohio
Accepted for publication May 6, 1997.
Background. Patients bridged to transplantation (TX) with the implantable left ventricular assist device (LVAD) may be at increased risk for the development of panel-reactive antibodies (PRA) during support.
Methods. To investigate that, we evaluated 60 patients who received the HeartMate LVAD at our institution, of whom 53 had PRA results available for analysis. T lymphocyte PRA levels were examined before LVAD, at the peak PRA level during LVAD support (PEAK), and just before TX. A PRA level more than 10% was considered indicative of sensitization against HLA antigens.
Results. The only factor that had a significant effect on PRA levels before LVAD was patient's sex (1.3% for men versus 7.4% for women; p = 0.005). During LVAD support, peak PRA levels increased significantly and the sex-associated differences were no longer evident (33.3% men, 34.3% women; not significant). At the time of TX, PRAs decreased to 10.9% (men) and 7.0% (women) (not significant). We examined the influence of blood products received before TX on PRA levels. Patients who received less than the median number of total units (<median) had lower peak PRA values (22.3% versus 49.2%; p = 0.01) and TX PRA values (3.5% versus 22.1%; p = 0.02) than those receiving more than the median (>median). When examined by the type of blood product, only the number of platelet transfusions significantly increased the peak PRA (<median: 24% versus >median: 46.9%; p = 0.03). Patients who received blood that was leukocyte-depleted tended to have lower TX PRA levels (2.9%) compared with those who did not (13.9%, p = 0.18). Forty-two patients were successfully bridged to TX, with three early and two late deaths after TX. Whereas 39 patients received transplants without intervention, 3 were treated by plasmapheresis with a 77% reduction in their HLA antibody levels at TX as measured by flow cytometry.
Conclusions. Patients with the implantable LVAD are at significant risk for the development of anti-HLA antibodies during support. Although this sensitization is often transient, intervention using plasmapheresis may be useful for some patients.
This article has been cited by other articles:
|
|
 |
|
  R. Malickaite, K. Rucinskas, A. Staneviciene, S. Miniauskas, V. Maneikiene, G. Zuoziene, and V. Sirvydis Sensitisation and post-transplant course after the implantation of ventricular assist device Interactive CardioVascular and Thoracic Surgery, March 1, 2009; 8(3): 339 - 343. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Kirsch, T. Timmermans, O. Van Caenegem, O. Gurne, P. Noirhomme, L.-M. Jacquet, D. Latinne, and A. J. Poncelet Allosensitization in bridge to transplant Novacor left ventricular assist device patients: analysis of long-term outcomes with regard to acute rejection and chronic allograft vasculopathy. Eur. J. Cardiothorac. Surg., August 1, 2008; 34(2): 268 - 274. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. P. Griffith, M. Haddad, and R. S. Poston Immunobiology of Heart and Heart-Lung Transplantation Card. Surg. Adult, January 1, 2008; 3(2008): 1513 - 1538. [Full Text]
|
|
|
|
 |
|
 L. U. Nwakanma, J. A. Williams, E. S. Weiss, S. D. Russell, W. A. Baumgartner, and J. V. Conte Influence of Pretransplant Panel-Reactive Antibody on Outcomes in 8,160 Heart Transplant Recipients in Recent Era Ann. Thorac. Surg., November 1, 2007; 84(5): 1556 - 1563. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Drakos, J. C. Stringham, J. W. Long, E. M. Gilbert, T. C. Fuller, B. K. Campbell, B. D. Horne, M. E. Hagan, K. E. Nelson, J. M. Lindblom, et al. Prevalence and risks of allosensitization in HeartMate left ventricular assist device recipients: The impact of leukofiltered cellular blood product transfusions J. Thorac. Cardiovasc. Surg., June 1, 2007; 133(6): 1612 - 1619. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Klotz, J. Stypmann, H. Welp, C. Schmid, G. Drees, A. Rukosujew, and H. H. Scheld Does Continuous Flow Left Ventricular Assist Device Technology Have a Positive Impact on Outcome Pretransplant and Posttransplant? Ann. Thorac. Surg., November 1, 2006; 82(5): 1774 - 1778. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. G. Drakos, A. G. Kfoury, J. W. Long, J. C. Stringham, T. C. Fuller, K. E. Nelson, B. K. Campbell, E. M. Gilbert, and D. G. Renlund Low-dose prophylactic intravenous immunoglobulin does not prevent HLA sensitization in left ventricular assist device recipients. Ann. Thorac. Surg., September 1, 2006; 82(3): 889 - 893. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Schenk, L. Arusoglu, M. Morshuis, K. Minami, P. Sarnowski, R. Koerfer, and A. El-Banayosy Triple Bridge-to-Transplant in a Case of Giant Cell Myocarditis Complicated by Human Leukocyte Antigen Sensitization and Heparin-Induced Thrombocytopenia Type II Ann. Thorac. Surg., March 1, 2006; 81(3): 1107 - 1109. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-M. Grinda, M.-O. Bricourt, C. Amrein, S. Salvi, R. Guillemain, A. Francois, P. Guibourt, A. Deloche, and J.-N. Fabiani Human Leukocyte Antigen Sensitization in Ventricular Assist Device Recipients: A Lesser Risk With the DeBakey Axial Pump Ann. Thorac. Surg., September 1, 2005; 80(3): 945 - 948. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. C. Ballew and J. D. Bergin Management of Patients With Preformed Reactive Antibodies Who Are Awaiting Cardiac Transplantation Am. J. Crit. Care., January 1, 2005; 14(1): 46 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. S. Kumpati, D. J. Cook, E. H. Blackstone, J. Rajeswaran, A. S. Abdo, J. B. Young, R. C. Starling, N. G. Smedira, and P. M. McCarthy HLA sensitization in ventricular assist device recipients: Does type of device make a difference? J. Thorac. Cardiovasc. Surg., June 1, 2004; 127(6): 1800 - 1807. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Poston and B. P. Griffith Heart Transplantation J Intensive Care Med, January 1, 2004; 19(1): 3 - 12. [Abstract] [PDF]
|
|
|
|
|
|
R. John, K. Lietz, M. Schuster, Y. Naka, V. Rao, D. M. Mancini, E. A. Rose, C. R. Smith, M. C. Oz, N. M. Edwards, et al. Immunologic sensitization in recipients of left ventricular assist devices J. Thorac. Cardiovasc. Surg., March 1, 2003; 125(3): 578 - 591. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. P. Griffith and R. S. Poston Immunobiology of Heart and Heart-Lung Transplantation Card. Surg. Adult, January 1, 2003; 2(2003): 1403 - 1426. [Full Text]
|
|
|
|
 |
|
 L. W. Stevenson and R. L. Kormos Mechanical cardiac support 2000: current applications and future trial design: June 15-16, 2000 Bethesda, Maryland J. Am. Coll. Cardiol., January 1, 2001; 37(1): 340 - 370. [Full Text] [PDF]
|
|
|
|
|
|
E. S. Bishay, D. J. Cook, R. C. Starling, N. B. Ratliff Jr., J. White, E. H. Blackstone, N. G. Smedira, and P. M. McCarthy The clinical significance of flow cytometry crossmatching in heart transplantation Eur. J. Cardiothorac. Surg., April 1, 2000; 17(4): 362 - 369. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L.S. Morales, K. A. Catanese, D. N. Helman, M. R. Williams, A. Weinberg, D. J. Goldstein, E. A. Rose, and M. C. Oz SIX-YEAR EXPERIENCE OF CARING FOR FORTY-FOUR PATIENTS WITH A LEFT VENTRICULAR ASSIST DEVICE AT HOME: SAFE, ECONOMICAL, NECESSARY J. Thorac. Cardiovasc. Surg., February 1, 2000; 119(2): 251 - 259. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-J. Ankersmit, N. M. Edwards, M. Schuster, R. John, A. Kocher, E. A. Rose, M. Oz, and S. Itescu Quantitative Changes In T-Cell Populations After Left Ventricular Assist Device Implantation : Relationship to T-Cell Apoptosis and Soluble CD95 Circulation, November 9, 1999; 100 (2009): II-211 - II-215. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. John, K. Lietz, E. Burke, J. Ankersmit, D. Mancini, N. Suciu-Foca, N. Edwards, E. Rose, M. Oz, and S. Itescu Intravenous Immunoglobulin Reduces Anti-HLA Alloreactivity and Shortens Waiting Time to Cardiac Transplantation in Highly Sensitized Left Ventricular Assist Device Recipients Circulation, November 9, 1999; 100 (2009): II-229 - II-235. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Itescu, E. Burke, K. Lietz, R. John, D. Mancini, R. Michler, E. Rose, M. Oz, and N. Edwards Intravenous Pulse Administration of Cyclophosphamide Is an Effective and Safe Treatment for Sensitized Cardiac Allograft Recipients Circulation, March 12, 2002; 105(10): 1214 - 1219. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
